Drug Type Small molecule drug |
Synonyms OFC, Olanzapine/fluoxetine, Symbyax + [2] |
Mechanism D1 receptor antagonists(Dopamine D1 receptor antagonists), D2 receptor antagonists(Dopamine D2 receptor antagonists), SERT inhibitors(Serotonin transporter inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date US (19 Mar 2009), |
Regulation- |
Molecular FormulaC34H39ClF3N5OS |
InChIKeyNEXXMCBZLDDQNK-UHFFFAOYSA-N |
CAS Registry250603-12-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Fluoxetine Hydrochloride/Olanzapine | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Bipolar and Related Disorders | CN | 30 Jun 2023 | |
Bipolar I disorder | US | 19 Mar 2009 | |
Depressive Disorder, Treatment-Resistant | US | 19 Mar 2009 |
Phase 3 | 892 | Olanzapine+Fluoxetine (OFC (SPIV)) | zxupvgzndl(onvxvpfvno) = fdcehyzmkx kjlqoxxasx (dygtoonctc, wiijktrcfh - mzbxsbpjue) View more | - | 01 Apr 2014 | ||
Fluoxetine (Flu) (Flu (SPIV)) | zxupvgzndl(onvxvpfvno) = kzkomzipuy kjlqoxxasx (dygtoonctc, xvzmnwdzid - swpvwgbwhj) View more |